Archive

Why penicillin allergy labels might be a bad thing

Written by | 13 Nov 2023

Neil Powell combines the roles of a consultant antimicrobial pharmacist and a clinical researcher at the Royal Cornwall Hospital in Truro.  His current research is focused on the […]

Establishing a community pharmacist-led vitamin D point-of-care testing service

Written by | 1 Nov 2023

Adequate levels of Vitamin D are critical for satisfactory immune function and this has stimulated interest in point-of-care testing (POCT) in community pharmacies. A pilot study has recently […]

What point-of-care testing for vitamin D levels tells us

Written by | 31 Oct 2023

The pilot study of pharmacist-led vitamin D point-of-care testing showed that the procedure was feasible in routine practice and, surprisingly, that more than half of participants had insufficient […]

Why should vitamin D levels be measured in community pharmacy?

Written by | 30 Oct 2023

Adequate levels of Vitamin D are critical for satisfactory immune function and this has stimulated interest in point-of-care testing (POCT) in community pharmacies. A pilot study has recently […]

STEP-HFpEF trial – caveats and implications

Written by | 19 Oct 2023

STEP-HFpEF was a randomised, controlled trial designed to find out whether semaglutide for 52 weeks could improve heart failure symptoms and physical function in obese, non-diabetic patients with […]

Semaglutide for prevention or cure of HFpEF?

Written by | 18 Oct 2023

The results of the STEP-HFpEF trial point towards routine use of GLP-1 agonists in heart failure but this has to be balanced against conflicting guidelines and cost pressures […]

How semaglutide impacts HFpEF

Written by | 17 Oct 2023

The results of the STEP-HFpEF trial showed statistically significant benefits “across the board” and these benefits were not due to weight loss alone, according to Vicky Ruszala, Specialist […]

Could semaglutide help obese patients with heart failure?

Written by | 16 Oct 2023

STEP-HFpEF was a randomised, controlled trial designed to find out whether semaglutide for 52 weeks could improve heart failure symptoms and physical function in obese, non-diabetic patients with […]

Making sense of GLP-1 agonists

Written by | 29 Sep 2023

GLP-1 receptor agonists (GLP-1RAs) such as semaglutide were developed for treatment of type II diabetes but have also been successful as weight-loss agents for non-diabetics. Many new agents […]

What does a consultant pharmacist in diabetes do?

Written by | 28 Sep 2023

The work of a consultant pharmacist in diabetes spans clinical duties and leadership tasks including education and mentoring. There are at present only three consultant pharmacists in diabetes […]

Should GLP-1 agonists should be used earlier in type 2 diabetes?

Written by | 27 Sep 2023

In the future, GLP-1 agonists could be used early in treatment for type II diabetes and this could have an important impact on slowing the onset of complications, […]

How GLP-1 agonists help in type 2 diabetes

Written by | 26 Sep 2023

GLP-1 agonists such as semaglutide were developed for treatment of type II diabetes but have also been successful as weight-loss agents for non-diabetics. Many new agents are now […]

Newsletter Icon

Sign up to our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare news and e-journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Sign Up

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our email journals and publications.